Follicular lymphomas (FLs) are a heterogeneous group of lymphomas. No standard of care exists, and the management of these patients is highly individualized.
Methods
After reviewing the scientific literature pertaining to the prognosis and management of FLs, we describe recent developments in treatment and discuss future trends in the care of patients with this disease.
Results
With the exception of a subset of patients with limited-stage FL treated with radiation therapy, no curative treatment exists for the majority of patients with FL. The decision on when to start treatment is based on the presence of symptoms, bulky disease, or abnormalities in hematologic parameters that can be attributed to FL. Prognostic scoring systems such as the Follicular Lymphoma International Prognostic Index help in assessing prognosis but do not contribute to the decision on when to start treatment. There are numerous effective chemotherapeutic regimens for the treatment of advanced-stage FL, but none show a definitive improvement in overall survival. Maintenance and consolidation regimens have also been shown to be effective treatments of FL, with significant improvements in progression-free survival and possibly overall survival.
Conclusions
Newer prognostic tests are in development that may help to guide the decision on which patients may benefit from early treatment. In addition, newer targeted agents that may improve on existing outcomes with less toxicity are currently being evaluated.
References
1.
GlassA.G., KarnellL.H., MenckH.R.. The National Cancer Data Base report on non-Hodgkin's lymphoma.Cancer.1997; 80(12): 2311–2320.
2.
SwerdlowS.H., CampoE., HarrisN.L.. World Health OrganizationClassification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Lyon, France: IARC Press; 2008.
3.
WeissL.M., WarnkeR.A., SklarJ.. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.N Engl J Med.1987; 317(19): 1185–1189.
4.
VauxD.L., CoryS., AdamsJ.M.. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.Nature.1988; 335(6189): 440–442.
5.
RoullandS., NavarroJ.M., GrenotP.. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.J Exp Med.2006; 203(11): 2425–2431.
6.
BentzM., WernerC.A., DöhnerH.. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma.Blood.1996; 88(4): 1437–1444.
7.
RoullandS., LebaillyP., LecluseY.. Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals.Leukemia.2006; 20(1): 158–162.
8.
DaveS.S., WrightG., TanB.. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.N Engl J Med.2004; 351(21): 2159–2169.
9.
Solal-CélignyP., RoyP., ColombatP.. Follicular lymphoma international prognostic index.Blood.2004; 104(5): 1258–1265.
10.
FedericoM., BelleiM., MarcheselliL.. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.J Clin Oncol.2009; 27(27): 4555–4562.
11.
O'SheaD., O'RiainC., TaylorC.. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.Blood.2008; 112(8): 3126–3129.
12.
WrenchD., LeightonP., SkibolaC.F.. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma.Blood.2011; 117(11): 3147–3150.
13.
AlvaroT., LejeuneM., SalvadóM.T.. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.J Clin Oncol.2006; 24(34): 5350–5357.
14.
GuadagnoloB.A., LiS., NeubergD.. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy.Int J Radiat Oncol Biol Phys.2006; 64(3): 928–934.
15.
ColombatP., SallesG., BrousseN.. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.Blood.2001; 97(1): 101–106.
16.
WitzigT.E., VukovA.M., HabermannT.M.. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.J Clin Oncol.2005; 23(6): 1103–1108.
17.
DavisT.A., Grillo-L6pezA.J., WhiteC.A.. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment.J Clin Oncol.2000; 18(17): 3135–3143.
18.
MarcusR., ImrieK., Solal-CelignyP.. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.J Clin Oncol.2008; 26(28): 4579–4586.
19.
HiddemannW., KnebaM., DreylingM.. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood.2005; 106(12): 3725–3732.
20.
RummelM.J., NiederleN., MaschmeyerG.. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).Blood (ASH Annual Meeting Abstracts).2009; 114: 405.
21.
TsimberidouA.M., McLaughlinP., YounesA.. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.Blood.2002; 100(13): 4351–4357.
22.
KaminskiM.S., TuckM., EstesJ.. 131I-tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med.2005; 352(5): 441–449.
23.
KaminskiM.S., TuckM., EstesJ.. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results.Blood (ASH Annual Meeting Abstracts).2009; 114: 3759.
24.
ScholzC.W., PintoA., LinkeschW.. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma: first results from an international phase II clinical trial.Blood (ASH Annual Meeting Abstracts).2010; 116: 593.
25.
MorschhauserF., RadfordJ., Van HoofA.. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol.2008; 26(32): 5156–5164.
26.
HagenbeekA., RadfordJ., Van HoofA.. 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced-stage follicular Non-Hodgkin's lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III first-line indolent trial (FIT) in 414 patients.Blood (ASH Annual Meeting Abstracts).2010; 116: 594.
27.
SallesG., SeymourJ.F., OffnerF.. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.Lancet.2011; 377(9759): 42–51.
28.
HainsworthJ.D., LitchyS., ShafferD.W.. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network.J Clin Oncol.2005; 23(6): 1088–1095.
29.
HochsterH.S., WellerE., GascoyneR.D.. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.Blood (ASH Annual Meeting Abstracts).2005; 106: 349.
30.
ForstpointnerR., UnterhaltM., DreylingM.. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).Blood.2006; 108(13): 4003–4008.
31.
GhielminiM., SchmitzS.F., CogliattiS.B.. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood.2004; 103(12): 4416–4423.
32.
van OersM.H., KlasaR., MarcusR.E.. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.Blood.2006; 108(10): 3295–3301.
33.
VidalL., Gafter-GviliA., LeiboviciL.. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.J Natl Cancer Inst.2009; 101(4): 248–255.
34.
SebbanC., BriceP., DelarueR.. Impact of rituximab and/or highdose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.J Clin Oncol.2008; 26(21): 3614–3620.
35.
van BesienK., LoberizaF.R.Jr, BajorunaiteR.. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.Blood.2003; 102(10): 3521–3529.
36.
HariP., CarrerasJ., ZhangM.J.. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.Biol Blood Marrow Transplant.2008; 14(2): 236–245.
37.
KhouriI.F., McLaughlinP., SalibaR.M.. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.Blood.2008; 111(12): 5530–5536.
38.
TeelingJ.L., FrenchR.R., CraggM.S.. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.Blood.2004; 104(6): 1793–1800.
39.
HagenbeekA., GadebergO., JohnsonP.. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.Blood.2008; 111(12): 5486–5495.
40.
HagenbeekA., FayadL., DelwailV.. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma.Blood (ASH Annual Meeting Abstracts).2009; 114: 935.
41.
MössnerE., BrünkerP., MoserS.. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.Blood.2010; 115(22): 4393–4402.
42.
SallesG.A., MorschhauserF., ThieblemontC.. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pretreated NHL patients: updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL).Blood (ASH Annual Meeting Abstracts).2010; 116: 2868.
43.
SatoS., TuscanoJ.M., InaokiM.. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.Semin Immunol.1998; 10(4): 287–297.
44.
LeonardJ.P., ColemanM., KetasJ.C.. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.J Clin Oncol.2003; 21(16): 3051–3059.
45.
LeonardJ.P., SchusterS.J., EmmanouilidesC.. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.Cancer.2008; 113(10): 2714–2723.
46.
GrantB., LeonardJ.P., JohnsonJ.L.. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701: a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20).Blood (ASH Annual Meeting Abstracts).2010; 116: 427.
47.
RamsayA.G., ClearA.J., KellyG.. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.Blood.2009; 114(21): 4713–4720.
48.
ChangD.H., LiuN., KlimekV.. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.Blood.2006; 108(2): 618–621.
49.
AhmadiT., ChongE.A., GordonA.. Phase II trial of lenalidomide - dexamethasone - rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab.Blood (ASH Annual Meeting Abstracts).2010; 116: 3962.
50.
LannuttiB.J., MeadowsS.A., HermanS.E.. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood.2011; 117(2): 591.
